Shares of US rare disease drugmaker Reata Pharmaceuticals (Nasdaq: RETA) shot up 52.8% to $165.90 by mid-morning today, on news of a takeover bid.
Biogen (Nasdaq: BIIB) has agreed to acquire Reata for $172.50 per share in cash, a nearly 60% premium from Reata’s share price at Thursday’s close, reflecting an enterprise value of around $7.3 billion. Markets clearly approved of the move, unusually, sending the buyer’s share up 1% pre-market.
Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s Food and Drug Administration (FDA)-approved Skyclarys (omaveloxolone) is the first and only approved treatment for Friedreich’s ataxia (FA) in the USA, with a commercial launch underway, and European regulatory review ongoing. In addition, Reata is developing a portfolio of innovative products for a range of neurological diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze